HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Investors in Kiromic BioPharma, Inc. (KRBP) with Significant Losses to Contact Firm’s Attorneys, Firm Investigating Possible Securities ...
Kiromic BioPharma, Inc. (KRBP)
Company Research
Source: GlobeNewswire
SAN FRANCISCO, April 04, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. The firm is investigating Kiromic’s possible securities law violations. Visit: https://www.hbsslaw.com/investor-fraud/KRBP Contact An Attorney Now: KRBP@hbsslaw.com | 844-916-0895 Kiromic BioPharma, Inc. (KRBP) Investigation: The investigation focuses on Kiromic’s disclosures about its development of two cancer treatment product candidates, ALEXIS-PRO-1 and ALEXIS-ISO-1. In the past, Kiromic has touted (1) the fact that it submitted two pre-initial new drug (“IND”) applications for its product candidates with the FDA on May 14 and May 17, 2021, and (2) its expectation that first human dosing in Phase I of clinical trials will commence in Q3 2021. Kiromic’s statements allowed the Company to raise $40 million in a July 2021 public offering. But on July 16, 2021, Kiromic disclosed th
Show less
Read more
Impact Snapshot
Event Time:
KRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRBP alerts
High impacting Kiromic BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
KRBP
News
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients [Yahoo! Finance]Yahoo! Finance
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsBusiness Wire
- Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialBusiness Wire
- Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial [Yahoo! Finance]Yahoo! Finance
KRBP
Sec Filings
- 5/10/24 - Form 10-Q
- 5/9/24 - Form 3
- 5/9/24 - Form SC
- KRBP's page on the SEC website